Ionis Pharmaceuticals Stock Alpha and Beta Analysis
| IONS Stock | USD 32.96 0.06 0.18% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Ionis Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Ionis Pharmaceuticals over a specified time horizon. Remember, high Ionis Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Ionis Pharmaceuticals' market risk premium analysis include:
Beta 0.89 | Alpha (0.02) | Risk 2.51 | Sharpe Ratio (0.08) | Expected Return (0.21) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Ionis |
Ionis Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Ionis Pharmaceuticals market risk premium is the additional return an investor will receive from holding Ionis Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Ionis Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Ionis Pharmaceuticals' performance over market.| α | -0.02 | β | 0.89 |
Ionis Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Ionis Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Ionis Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Ionis Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Ionis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ionis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Ionis Pharmaceuticals stock market price indicators, traders can identify Ionis Pharmaceuticals position entry and exit signals to maximize returns.
Ionis Pharmaceuticals Return and Market Media
The median price of Ionis Pharmaceuticals for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 33.41 with a coefficient of variation of 6.23. The daily time series for the period is distributed with a sample standard deviation of 2.11, arithmetic mean of 33.89, and mean deviation of 1.75. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Baroldi Joseph of 2500 shares of Ionis Pharmaceuticals at 34.69 subject to Rule 16b-3 | 01/02/2025 |
2 | Ionis Pharmaceuticals Insiders Sold US3.2m Of Shares Suggesting Hesitancy | 01/23/2025 |
3 | Acquisition by Bennett C Frank of 3607 shares of Ionis Pharmaceuticals subject to Rule 16b-3 | 01/30/2025 |
4 | Disposition of 1406 shares by Oneil Patrick R. of Ionis Pharmaceuticals at 32.4926 subject to Rule 16b-3 | 02/03/2025 |
5 | Insider Sell Brett Monia Sells Shares of Ionis Pharmaceuticals Inc | 02/07/2025 |
6 | Ionis Pharmaceuticals Reports Q4 Earnings What Key Metrics Have to Say | 02/19/2025 |
7 | Ionis Pharmaceuticals Inc Q4 2024 Earnings Call Highlights Surpassing Revenue ... | 02/20/2025 |
8 | Ionis Pharmaceuticals Announces Earnings Results | 02/21/2025 |
9 | Global Amyloidosis Therapeutics Market Outlook to Exceed US 6.3 Billion by 2035 at 8.2 percent CAGR, Driven by Rising Disease Prevalence and Robust RD Investmen... | 02/24/2025 |
10 | Ionis Pharmaceuticals, Inc. EVP Patrick R. Oneil Sells 1,207 Shares | 02/25/2025 |
11 | Acquisition by Bennett C Frank of 320 shares of Ionis Pharmaceuticals at 28.2115 subject to Rule 16b-3 | 02/28/2025 |
12 | Disposition of 12295 shares by Devers Shannon L. of Ionis Pharmaceuticals subject to Rule 16b-3 | 03/03/2025 |
13 | Acquisition by Devers Shannon L. of 22000 shares of Ionis Pharmaceuticals at 34.69 subject to Rule 16b-3 | 03/04/2025 |
14 | How Is Ionis Pharmaceuticals Expanding Its RNA-Targeted Therapeutics Portfolio | 03/07/2025 |
15 | WAINZUA approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy | 03/10/2025 |
16 | Acquisition by Elizabeth Hougen of 23887 shares of Ionis Pharmaceuticals subject to Rule 16b-3 | 03/12/2025 |
About Ionis Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Ionis or other stocks. Alpha measures the amount that position in Ionis Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 15.88 | 45.31 | 47.72 | 45.33 | PTB Ratio | 9.35 | 18.71 | 8.88 | 8.44 |
Ionis Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Ionis Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ionis Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Ionis Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Ionis Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Ionis Pharmaceuticals' management manipulating its earnings.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Ionis Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.